Profile data is unavailable for this security.
About the company
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
- Revenue in USD (TTM)0.00
- Net income in USD-53.47m
- Incorporated2008
- Employees68.00
- LocationImmuneering Corp245 Main St Fl 2CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 500-8080
- Fax+1 (302) 655-5049
- Websitehttps://immuneering.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics Inc | 675.00k | -31.41m | 38.93m | 14.00 | -- | -- | -- | 57.67 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Ocuphire Pharma Inc | 19.05m | -9.99m | 39.33m | 14.00 | -- | 0.7615 | -- | 2.06 | -0.4735 | -0.4735 | 0.8727 | 2.08 | 0.3701 | -- | 5.30 | 1,360,643.00 | -19.40 | -58.31 | -20.77 | -65.94 | -- | -- | -52.42 | -137.92 | -- | -8.46 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 39.58m | 57.00 | -- | 0.6907 | -- | 17.68 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 39.82m | 5.00 | -- | 5.87 | -- | 98.38 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Cara Therapeutics Inc | 20.97m | -118.51m | 41.10m | 55.00 | -- | 0.7176 | -- | 1.96 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Aspira Women's Health Inc | 9.15m | -16.69m | 41.44m | 64.00 | -- | -- | -- | 4.53 | -1.73 | -1.73 | 0.9683 | -0.2222 | 0.7746 | 14.34 | 6.77 | 143,031.30 | -141.23 | -110.58 | -256.99 | -151.88 | 57.48 | 45.23 | -182.32 | -334.08 | 0.9871 | -- | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 41.60m | 1.00 | -- | 0.2323 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Yubo International Biotech Ltd | 604.68k | -1.20m | 41.78m | 18.00 | -- | -- | -- | 69.10 | -0.01 | -0.01 | 0.005 | -0.0154 | 0.3012 | 0.6912 | 9.19 | 33,593.33 | -59.52 | -- | -- | -- | 69.32 | -- | -197.64 | -- | 0.1504 | -3,143.97 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Dyadic International Inc | 2.90m | -6.80m | 41.81m | 7.00 | -- | 7.01 | -- | 14.42 | -0.2359 | -0.2359 | 0.1007 | 0.204 | 0.2643 | -- | 7.28 | 414,115.70 | -61.97 | -36.82 | -78.87 | -39.85 | 31.84 | 22.47 | -234.42 | -410.16 | -- | -- | 0.00 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 41.92m | 8.00 | -- | 8.76 | -- | 38.95 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Immuneering Corp | 0.00 | -53.47m | 42.11m | 68.00 | -- | 0.4589 | -- | -- | -1.89 | -1.89 | 0.00 | 3.09 | 0.00 | -- | -- | 0.00 | -47.54 | -- | -51.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 7.88m | -69.20m | 42.13m | 100.00 | -- | 0.3736 | -- | 5.35 | -1.83 | -1.83 | 0.2083 | 2.96 | 0.0406 | -- | -- | 78,760.00 | -35.71 | -48.32 | -40.23 | -54.03 | -- | -- | -878.58 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| SensaSure Technologies Inc | 1.15k | -1.94m | 42.26m | 1.00 | -- | -- | -- | 36,749.47 | -0.0344 | -0.0344 | 0.00002 | -0.011 | 0.0336 | -- | -- | 1,150.00 | -5,689.09 | -- | -- | -- | -- | -- | -169,534.80 | -- | -- | -2.71 | -- | -- | -31.15 | -- | 17.62 | -- | -- | -- |
| Rockwell Medical Inc | 80.83m | -9.29m | 42.87m | 253.00 | -- | 1.93 | -- | 0.5304 | -0.5462 | -0.5462 | 4.26 | 0.7553 | 1.51 | 13.83 | 9.66 | 319,494.10 | -17.40 | -53.82 | -28.13 | -73.10 | 10.11 | 1.75 | -11.49 | -46.17 | 1.06 | -6.74 | 0.3517 | -- | 17.57 | 4.91 | 42.83 | -- | -30.09 | -- |
| Movano Inc | 0.00 | -29.28m | 43.71m | 30.00 | -- | 7.21 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| IN8BIO, Inc. | 0.00 | -30.01m | 44.90m | 31.00 | -- | 1.77 | -- | -- | -1.02 | -1.02 | 0.00 | 0.5761 | 0.00 | -- | -- | 0.00 | -89.91 | -74.18 | -108.07 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Data as of May 01 2024. Currency figures normalised to Immuneering Corp's reporting currency: US Dollar USD
32.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Advisors LLCas of 31 Dec 2023 | 2.06m | 7.02% |
| Cormorant Asset Management LPas of 03 Apr 2024 | 1.70m | 5.81% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.36m | 4.65% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.04m | 3.54% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 910.27k | 3.11% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 660.23k | 2.26% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 489.45k | 1.67% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 457.06k | 1.56% |
| Geode Capital Management LLCas of 31 Dec 2023 | 444.23k | 1.52% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 373.66k | 1.28% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
